ENST00000429896.6:c.-130A>G
Variant summary
Our verdict is Likely benign. The variant received -5 ACMG points: 0P and 5B. BP6BS2
The ENST00000429896.6(PTCH1):c.-130A>G variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000162 in 1,613,260 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
ENST00000429896.6 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Publications
- basal cell nevus syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- holoprosencephaly 7Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- holoprosencephalyInheritance: AD Classification: LIMITED Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -5 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: ENST00000429896.6. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | NM_000264.5 | MANE Select | c.324A>G | p.Ile108Met | missense | Exon 2 of 24 | NP_000255.2 | ||
| PTCH1 | NM_001083603.3 | MANE Plus Clinical | c.321A>G | p.Ile107Met | missense | Exon 2 of 24 | NP_001077072.1 | ||
| PTCH1 | NM_001083604.3 | c.-130A>G | 5_prime_UTR_premature_start_codon_gain | Exon 2 of 24 | NP_001077073.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | ENST00000429896.6 | TSL:1 | c.-130A>G | 5_prime_UTR_premature_start_codon_gain | Exon 2 of 24 | ENSP00000414823.2 | |||
| PTCH1 | ENST00000546820.5 | TSL:1 | c.-130A>G | 5_prime_UTR_premature_start_codon_gain | Exon 2 of 7 | ENSP00000448843.1 | |||
| PTCH1 | ENST00000547672.5 | TSL:1 | c.-130A>G | 5_prime_UTR_premature_start_codon_gain | Exon 2 of 7 | ENSP00000447878.1 |
Frequencies
GnomAD3 genomes AF: 0.0000921 AC: 14AN: 151938Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000837 AC: 21AN: 250768 AF XY: 0.0000884 show subpopulations
GnomAD4 exome AF: 0.000169 AC: 247AN: 1461322Hom.: 1 Cov.: 31 AF XY: 0.000168 AC XY: 122AN XY: 726970 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000921 AC: 14AN: 151938Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74226 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
The PTCH1 p.Ile108Met variant was not identified in the literature nor was it identified in Cosmic, MutDB or LOVD 3.0. The variant was identified in dbSNP (ID: rs144182921) and in ClinVar (classified as uncertain significance by Invitae for Gorlin syndrome, likely benign for hereditary cancer-predisposing syndrome by Ambry Genetics and as uncertain significance by Praxis fuer Humangenetik Tuebingen). The variant was identified in control databases in 25 of 282050 chromosomes at a frequency of 0.000089 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (Non-Finnish) in 21 of 128822 chromosomes (freq: 0.000163) and European (Finnish) in 4 of 25104 chromosomes (freq: 0.000159); it was not observed in the African, Latino, Ashkenazi Jewish, East Asian, Other and South Asian populations. The p.Ile108 residue is conserved in mammals but not in more distantly related organisms and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, and MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
Gorlin syndrome Benign:2
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign.
Hereditary cancer-predisposing syndrome Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Holoprosencephaly 7 Uncertain:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
not specified Benign:1
Variant summary: PTCH1 c.324A>G (p.Ile108Met) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8.4e-05 in 250768 control chromosomes (gnomAD). The observed variant frequency is approximately 5-fold of the estimated maximal expected allele frequency for a pathogenic variant in PTCH1 causing Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome) phenotype (1.7e-05), strongly suggesting that the variant is benign. c.324A>G has been reported in the literature in an individual affected with Kallmann Syndrome without signs of Gorlin Syndrome (Barraud_2020). This report does not provide unequivocal conclusions about association of the variant with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 32074614). Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, and classified it as likely benign (n=5) or uncertain significance (n=2). Based on the evidence outlined above, the variant was classified as likely benign.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at